cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
6 own
9 watching
Current Price
$159.05
$-2.99
(-1.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,301.92M
52-Week High
52-Week High
189.97000
52-Week Low
52-Week Low
82.09000
Average Volume
Average Volume
0.24M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization3,301.92M
icon52-Week High189.97000
icon52-Week Low82.09000
iconAverage Volume0.24M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
N/A
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
9 months ago
PITTSBURGH, July 03, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with debilitating diseases, announced today that the first patient has been dosed at the Cystic Fibrosis ...
Zolmax
1 year ago
Stifel Nicolaus initiated coverage on shares of Krystal Biotech (NASDAQ:KRYS Get Rating) in a research note released on Monday, The Fly reports. The brokerage issued a buy rating and a $102.00 price objective on the stock. KRYS has been the subject of a number of other reports. HC Wainwright ...
Ticker Report
1 year ago
Krystal Biotech, Inc. (NASDAQ:KRYS Get Rating) Director Dino A. Rossi sold 40,000 shares of the businesss stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $83.25, for a total value of $3,330,000.00. Following the transaction, the director ...
Globe Newswire
1 year ago
PITTSBURGH, March 02, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the43rd Annual TD Cowen Health ...
Globe Newswire
1 year ago
B-VEC PDUFA date May 19, 2023 Data from the pivotal Phase 3 (GEM-3) trial of B-VEC for dystrophic epidermolysis bullosa published in the New England Journal of Medicine Four pipeline clinical trials in dermatology, respiratory and aesthetics to initiate in 2023 Strong balance sheet, closing the ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$159.05
$-2.99
(-1.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00